The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD. The phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results